- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04945980
Ground Beef and Cardiovascular Disease
Manipulation of Beef Fatty Acids to Tailor Ground Beef Products to Individual Consumer Needs
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants and study design Healthy, nonsmoking males between the ages of 23 and 60 years were screened for eligibility. The 30 participants selected were not consuming restrictive diets or medications. Family histories were obtained as part of a complete physical examination that included a treadmill exercise test with an electrocardiogram. Baseline blood chemistries were analyzed by a local laboratory and all blood chemistries were within normal ranges as defined by the testing laboratory. All participants were free living and were instructed to maintain routine activities and body weight (62.2 kg of entry weight). Exercise and physical activities were not restricted, but participants were requested not to change their habitual level of physical activity. Twenty-seven of the initial 30 participants completed the study.
Of the 3 non-completers, 1 had a re-occurrence of a previous illness, another relocated, and data from the 3rd was omitted following baseline samples that showed high triglyceride concentrations (.5 mmol/L). A 2-period, randomized cross-over design was used. Each participant completed two 5-wk diet interventions in a randomly assigned order with a 4-wk washout period between the test diet interventions. The men consumed 5 ground beef patties per week for 5 wk during each dietary intervention (25 patties of each type for each ground beef intervention). The 2 interventions were low-monounsaturated fat ground beef and high-monounsaturated fat ground beef. To facilitate product distribution and blood sampling, participants were assigned to 1 of 2 groups, which were balanced with regard to age, body weight, and total cholesterol concentration at the initial screening. Group 1 began the study 2 wk before group 2. Both groups rotated through both test diets, but the pattern in which they crossed over differed between groups. Therefore, crossovers included all possible rotation sequences. Body weights were recorded weekly.
Collection and analysis of blood samples Prior to the initiation of the dietary treatments and at the end of each diet phase and after 5 minutes of seated rest, blood was collected from the participants into vacutainers from a vein in the antecubital fossa using standard phlebotomy procedures. Plasma was harvested from the blood collected with EDTA and lipoproteins preserved in plasma prior to lipoprotein separation using density gradient ultracentrifugation employing human density intervals. Determination of LDL lipoprotein diameters was by non-denaturing gradient gel electrophoresis. Particle diameters were determined by comparison with migration distances of standard proteins of known hydrated diameter. Plasma total lipoproteins isolated as the d < 1.2 kg/L fraction of plasma were separated on the basis of diameter with a gel-filtration chromatographic system to determine the relative distribution of plasma total cholesterol among very low-density lipoproteins (VLDL), LDL, and HDL lipoprotein classes. Concentrations of total cholesterol, triglycerides, and glucose in plasma were determined by separate enzymatic assays. Concentrations of serum insulin and serum C-reactive protein (CRP) were assayed using commercially available ELISA kits according to the manufacturers' instructions.
Statistical analysis We compared nutrient and dietary exchange data and final plasma glucose, lipids, insulin, CRP, and lipoprotein particle diameters to their corresponding baseline values by paired t test. Data were tested for unequal variance by the Breusch- Pagan/Cook-Weisberg test for heteroscedasticity to test the null hypothesis that the error variances were all equal. Values for changes from baseline for the low- and high-MUFA treatment groups were compared by 1-way analysis of variance, with ground beef type as the treatment effect. Associations among plasma analytes were assessed using Pearson correlation coefficients. P-values were considered significant at P < 0.05.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-smoking
Exclusion Criteria:
- Consuming restrictive diets, cholesterol-lowering medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Low-MUFA ground beef
Participants consumed ground beef low in monounsaturated fatty acids.
|
Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
|
EXPERIMENTAL: High-MUFA ground beef
Participants consumed ground beef high in monounsaturated fatty acids.
|
Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lipoprotein cholesterol
Time Frame: 5 weeks
|
Plasma very low-density, low-density, and high-density cholesterol concentrations
|
5 weeks
|
Low-density lipoprotein particle size
Time Frame: 5 weeks
|
Plasma low-density lipoprotein particle size
|
5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C-reactive protein
Time Frame: 5 weeks
|
Plasma C-reactive protein
|
5 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephen Smith, Ph.D., Texas A&M University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB2005-0435
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipoprotein Metabolism Disorder
-
University of Texas Southwestern Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Eli Lilly and CompanyActive, not recruitingLipoprotein DisorderUnited States, Spain, China, Japan, Germany, Argentina, Romania, Netherlands, Mexico, Denmark
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedProteomics | Lipoprotein Metabolism | PCSK9United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedProteomics | Lipoprotein Metabolism | PCSK9United States
-
Pamukkale UniversityBakirkoy Dr. Sadi Konuk Research and Training HospitalCompletedType2 Diabetes | Self Efficacy | Self Management | Cholesterol; Lipidosis | High Density Lipoprotein Deficiency | Motivational Interview | Tele-nursing | LDL - Low Density Lipoprotein Receptor DisorderTurkey
-
Eli Lilly and CompanyCompletedLipoprotein DisorderAustralia, China, Hungary, Brazil, Japan, Germany, Netherlands, United States
-
Amsterdam Molecular TherapeuticsInternational Antiviral Therapy Evaluation CenterUnknownFamilial Lipoprotein Lipase DeficiencyCanada
-
Amsterdam Molecular TherapeuticsThe Clinical Trial CompanyCompletedFamilial Lipoprotein Lipase DeficiencyCanada
-
Ionis Pharmaceuticals, Inc.Akcea TherapeuticsCompleted
-
Ionis Pharmaceuticals, Inc.CompletedElevated Lipoprotein(a)Netherlands, United Kingdom, Denmark, Germany, Canada
Clinical Trials on Ground beef
-
Texas A&M UniversityCompletedCholesterol, LDL | Cholesterol, HDL | Research SubjectsUnited States
-
University of MinnesotaCompleted
-
University of California, DavisRockefeller UniversityCompleted
-
Maastricht University Medical CenterCompleted
-
University of ArkansasCompleted
-
University of ArkansasCompletedProtein MetabolismUnited States
-
University of ArkansasCompletedProtein MetabolismUnited States
-
University of GuelphOntario Bean GrowersCompleted
-
Kasper DideriksenUnknownMuscle Protein Synthesis | Meat Protein Supplements | Protein Absorption and Amino Acid AvailabilityDenmark
-
Oxford University Hospitals NHS TrustActive, not recruitingCerebral Infarction | Intracranial Hemorrhages | Acute Ischemic Stroke | Cerebral Edema | Hydrocephalus | Cerebral InjuryUnited Kingdom